Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Extraparathyroid hypercalcemia]

R Rizzoli1, J P Bonjour

  • 1Département de médecine interne Hôpital cantonal universitaire, Genève.

La Revue Du Praticien
|October 22, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fracture history of healthy premenopausal women is associated with a reduction of cortical microstructural components at the distal radius.

Bone·2013
Same author

Fractures in healthy females followed from childhood to early adulthood are associated with later menarcheal age and with impaired bone microstructure at peak bone mass.

The Journal of clinical endocrinology and metabolism·2012
Same author

Fractures during childhood and adolescence in healthy boys: relation with bone mass, microstructure, and strength.

The Journal of clinical endocrinology and metabolism·2011
Same author

Pubertal timing and body mass index gain from birth to maturity in relation with femoral neck BMD and distal tibia microstructure in healthy female subjects.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2011
Same author

The influence of pubertal timing on bone mass acquisition: a predetermined trajectory detectable five years before menarche.

The Journal of clinical endocrinology and metabolism·2009
Same author

Nutrition and aging. The Carla Workshop.

The journal of nutrition, health & aging·2008
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Hypercalcemia, often caused by tumors in patients, results from increased calcium in the body. Bone resorption inhibitors like bisphosphonates are key for managing this condition.

Area of Science:

  • Endocrinology and Bone Metabolism
  • Oncology and Calcium Homeostasis

Context:

  • Hypercalcemia is a common complication in hospitalized patients.
  • Tumor-induced hypercalcemia is the most frequent cause in this population.
  • Pathophysiological mechanisms involve bone resorption and renal reabsorption.

Purpose:

  • To explain the origins and mechanisms of hypercalcemia.
  • To highlight the role of tumors in causing hypercalcemia.
  • To establish the rationale for using bone resorption inhibitors.

Summary:

  • Hypercalcemia arises from increased calcium in extracellular fluid, primarily from bone resorption and renal reabsorption.
  • Malignancy is the leading cause of hypercalcemia in inpatients, driven by enhanced bone resorption and renal calcium retention.

Related Experiment Videos

  • Hyperosteolysis, or excessive bone breakdown, in non-parathyroid hypercalcemia supports the use of bisphosphonates for acute treatment.

    • Impact:

    • Informs clinical management strategies for hypercalcemia.
    • Highlights the significance of bisphosphonates in treating tumor-related hypercalcemia.
    • Contributes to understanding calcium dysregulation in oncological and endocrine disorders.